CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.